Vyome Therapeutics

Vyome Therapeutics is a biopharmaceutical company focused on developing novel drugs to combat antibiotic-resistant acne and other opportunistic pathogens. The company offers a range of products, including VB 1953, its lead molecule aimed at addressing the unmet needs in the drug-resistant acne market, as well as DARTS, which prevents resistance development in acne and other pathogens. Additionally, Vyome's portfolio includes various anti-dandruff treatments, such as VB 001, an anti-dandruff scalp care product, VB 2421, an anti-dandruff hair gel, VB 3222, a wash-off shampoo, and VB 7731, a Ketoconazole emulsion gel. Established in 2010 and headquartered in Princeton, New Jersey, Vyome Therapeutics is committed to innovation through its risk-mitigated development platform and state-of-the-art research infrastructure. The company aims to provide effective solutions for refractory skin conditions, enhancing treatment options for patients and healthcare professionals.